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Cryopyrin is predominantly expressed in 
monocytes and granulocytes. Cryopyrin 
contains three domains: a pyrin domain 
(PYD), a nucleoside oligomerization 
domain (NOD), and a domain of leucine-
rich repeats (LRR).10 Crypoyrin is able to 
associate with other proteins to form a 
complex termed the inflammasome. The 
central component of the inflammasome 
is a member of the NALP family (in case 
of the cryopyrin inflammasome: 
cryopyrin). It associates with the adaptor 
protein ASC, which in turn recruits 
proinflammatory caspase precursors 
(such as procaspase-1) (Fig. 2). The 
conversion of procaspase-1 into caspase-
1 leads to the conversion of pro-IL-1� 
into IL-1�.12 IL-1� is a key mediator of 
inflammation, with a wide variety of 
effects ranging from induction of fever 
and extravasation of leukocytes to 
enhanced expression of adhesion 
molecules on endothelial cells and 
induction of bone resorption. 
 
Tumor necrosis factor receptor-
associated periodic syndrome 
TRAPS is caused by mutations in 
TNFRSF1A, located on chromosome 
12p13. The gene encodes TNF receptor 
superfamily 1A (TNFRSF1A), the main 
surface receptor for TNF.13 TNFRSF1A has three important domains: an extracellular 
ligand-binding domain, a transmembrane portion, and an intracellular effector domain 
(DD) belonging to the DD superfamily. More than 50 different TNFRSF1A mutations have 
been described that cause TRAPS. The TRAPS-associated mutations are all located within 
the extracellular domain of the molecule. The TNF receptor forms trimers after binding to 
its ligand. Upon binding of TNF, the intracellular DD recruits TRADD. TRADD is able to 
recruit other molecules to initiate a downstream signalling cascade leading to NF-kB 
activation and caspase-induced apoptosis (Fig. 3). Furthermore, upon receptor 
activation through TNF, the extracellular domain of the TNF receptor is shed from the 
Figure 1. Inflammatory mechanism of pyrin. Pyrin 
contains a PYD domain that can bind to 
apoptosis-associated speck-like protein (ASC). 
ASC in turn, can recruit caspase-1 via the CARD 
domain. Caspase-1 is capable of cleaving inactive 
proIL-1� into active IL-1�. 
Figure 2. The cryopyrin inflammasome. Cryopyrin is 
the central component of the cryopyrin 
inflammasome. Cryopyrin contains three domains: a 
pyrin domain (PYD), a nucleoside oligomerization 
domain (NOD), and a domain of leucine-rich 
repeats (LRR). Cryopyrin binds ASC through its PYD 
domain and through the NOD domain. The 
association of these proteins ultimately leads to the 
release of active caspase-1, which in turn activates 
IL-1� through the cleavage of proIL-1�. Upon its 
secretion into the extracellular milieu, IL-1� sets off 
a series of events that result in inflammation.  
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Autoinflammatory fever syndromes
membrane. This shedding of 
receptors leads to a pool of soluble 
TNF receptors that is thought to 
mitigate the immune response. Two 
hypotheses are offered to explain the 
inflammatory phenotype of TRAPS. 
The shedding hypothesis was first 
coined after the initial observation 
that patients with TRAPS have 
reduced serum levels of soluble TNF 
receptors. Furthermore, in vitro 
experiments showed that some 
mutated cell lines exhibit impaired 
shedding of TNF receptors.13 The 
defective shedding would lead to a 
deficiency of soluble TNF receptors that 
can scavenge excess TNF and diminish 
the immune response.  Furthermore, 
since receptors remain present on the 
membrane, there is ongoing 
stimulation of the cells. However, the 
shedding hypothesis fails to explain the 
complete phenotype, as not all TRAPS 
patients have defective shedding. 
Recently an alternative explanation, the 
so-called misfolding hypothesis, was 
proposed.14, 15 Several mutations in the 
extracellular domain of TNFRSF1A lead to misfolding of the molecule. The misfolded 
receptors are not expressed at the surface, but are retained intracellularly. In vitro results 
show that the aggregated TNFRSF1A retain signal function and can induce ligand-
independent  NF-kB activation and apoptosis. 
Hyperimmunoglobulin D and periodic fever syndrome 
HIDS is caused by mutations in the mevalonate kinase gene (MVK), located on the long 
arm of chromosome 12 (12q24). Mevalonate kinase is a key enzyme in the isoprenoid 
pathway and follows 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG coA 
reductase). In patients with HIDS, the activity of mevalonate kinase is reduced to 5–15% of 
normal levels.5 In the isoprenoid pathway cholesterol is produced in addition to a number 
of nonsterol isoprenoids. Isoprenoids are essential compounds in diverse cellular function 
and include ubiquinone, heme A, farnesyl, and geranyl. How a reduced activity of 
mevalonate kinase leads to an autoinflammatory condition in not known. It can be caused 
Figure 3. Proposed pathophysiology of tumor necrosis 
factor receptor-associated periodic syndrome (TRAPS). 
(1) Tumor necrosis factor (TNF) binds to the TNF 
receptor on the surface of inflammatory cells (2). After 
receptor triggering, TRADD is recruited and a signal 
leads to apoptosis and cytokine production (3). In 
healthy individuals the receptors are shed from the 
surface, leading to a pool of receptors that dampen 
immune response (4). In patients with TRAPS there is 
diminished shedding, which may lead to a 
proinflammatory state by ongoing stimulation of 
retained cell surface receptors. Alternatively, the 
deficiency of soluble TNF receptors reduces scavenging 
of excess TNF. (5) Other research has shown that 
mutated TNF receptors form aggregates and are 
retained intracellularly. These aggregated receptors are 
capable of binding TRADD and stimulate ligand-
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NOMID can be diagnosed based on characteristic clinical manifestations.  Mutational 
analysis is available (www.genedx.com), but in some patients no mutations are found. 
Tumor necrosis factor receptor associated periodic syndrome 
Clinical features 
TRAPS is inherited in an autosomal dominant manner. The age of onset varies widely, but 
most patients become symptomatic within the first few years of life. The median age of 
onset is 3 years. The usual duration of episodes in TRAPS is considerably longer than in 
the other autoinflammatory syndromes. An attack persists for a minimum of 3 days, but 
can last for weeks. The interval between attacks can vary substantially within a single 
patient. Localized myalgia affecting a limb associated with fever is found in virtually all 
patients.27 Patients describe it as a deep cramping muscle pain, often severely disabling.  
The symptoms are probably due to a monocytic fasciitis. Cutaneous manifestations are 
present in the large majority of patients during attacks. They consist of localized 
erythematous macules and patches that tend to migrate to the distal part of the 
extremities.28 Abdominal pain, often accompanied by vomiting, constipation, and bowel 
obstruction, occurs in almost all patients. Arthralgia and monoarticular arthritis involving 
hips, knees, and ankles are present in a quarter of patients at some point in the natural 
history of their disease. Chest pain is a frequent feature and may be either pleural in origin 
or reflect musculoskeletal involvement. 
Characteristic ocular symptoms in TRAPS range from conjunctivitis and periorbital pain to 
severe uveitis and iritis. Periorbital edema with conjunctival injection is another distinctive 
but infrequent feature of TRAPS. Other less frequently observed symptoms are pericarditis, 
and inflammation of the tunica vaginalis, leading to scrotal pain.  Lymphadenopathy is 
rare.  
Laboratory investigations 
During an attack of TRAPS laboratory 
investigations indicate an acute-phase 
response, with elevated erythrocyte 
sedimentation rate, CRP, haptoglobin, 
fibrinogen, and ferritin. A large proportion of 
patients also demonstrate an elevated acute-
phase response between clinically 
symptomatic attacks. Complete blood count 
may demonstrate neutrophilia, 
thrombocytosis, and anemia of chronic 
disease. Polyclonal gammopathy as well as 
small monoclonal gammopathy occur. 
Figure 4. Migrating erythemateous macular rash 
during an inflammatory attack in a tumor necrosis 
factor receptor-associated periodic syndrome 























































































cases of amyloidosis are found. Hopefully, with the recent progression in treatment, the 
number of new cases of amyloidosis will decrease in the near future. 
Although MWS was originally described as a triad of deafness, urticaria, and amyloidosis, 
not all patients with MWS develop amyloidosis.  Approximately one-third of patients 
develop amyloidosis, and there is familial clustering. Several cases have been described in 
FCAS and NOMID, but numbers are too small to make an accurate estimate of the 
prevalence. 
Patients with HIDS have a relatively small risk of developing amyloidosis. In fact, only 
recently the first cases of amyloidosis were described.  Still there is a remarkably lower 
incidence of amyloidosis in HIDS compared to the other periodic fever syndromes, despite 
a similar acute-phase response.  
A diagnosis of amyloidosis is confirmed by Congo red staining of affected tissues, showing 
a typical apple-green birefringence under polarized light microscopy (Fig. 5). Biopsy of 
subcutaneous fat or rectal tissue can be used to detect amyloid fibrils. If these are negative 
and there is a high index of suspicion, a direct biopsy from an affected organ can be 
considered.  
The prognosis of patients with established amyloidosis is grave, with a median survival of 
24–53 months. The natural history of amyloidosis is progression to renal failure. If 
inflammation cannot be controlled, amyloid deposits in a variety of organs (liver, spleen, 
gastrointestinal tract, heart) occur. As a consequence malabsorption with severe diarrhea 
may ensue. Cardiac failure and rhythm disturbances are typical manifestations of cardiac 
involvement. The progression of amyloidosis is strongly dependent on the ability to control 
the underlying inflammatory process. If the SAA concentration can be kept under 10 mg/l, 
progression of amyloidosis can be halted in many cases, and in some the amyloid mass 
even slowly regresses.31  
Figure 5. Tissue section of a renal biopsy from a patient with AA amyloidosis. Amyloid deposits are 
visualized by staining with Congo red (A). Under polarized light microscopy amyloid deposits 
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Lovastatin inhibits formation of AA amyloid
Results 
We were able to induce in vitro 
amyloidogenesis in a reproducible and 
consistent manner. We found that amyloidosis 
induction was initiated by the addition of SAA 
(150 �g/ml) and AEF to human monocytes. 
With this concentration, which is well within 
the range found during inflammatory attacks of 
HIDS patients, the first extracellular amyloid 
deposits appear as early as three days after the 
start of induction. The deposits stain with 
Congo-red and show typical apple-green 
birefringence under polarized light microscopy, 
indicative of amyloid fibrils (Figure 2). When 
induction of amyloidogenesis is prolonged, 
there is a gradual increase in the amount of 
amyloid as shown in Figure 3. For example, 
Congo-red material is present in approximately 
10% of the culture after 9-day incubation with 
SAA.  
Next, we investigated the effect of the HMG-
CoA reductase inhibitor lovastatin on amyloid 
Figure 2. Extracellular Congo red deposits 
after 5 days of incubation with 150 �g/ml 
SAA and AEF (A). The Congo red deposits 
show typical apple-green birefringence 
under polarized light (B). 
Figure 3. Deposition of amyloid during time. Mononuclear cells were incubated with 150 �g/ml SAA 






























































































































































































































































































































































































































































detected by staining the cells with Congo red. As shown in Figure 1, after 7 days of 
incubation cells of healthy volunteers make amyloid fibrils only when they are 
simultaneously exposed to AEF. However, monocytes from the patient with AL amyloidosis 
showed extensive AA amyloid deposition even without co-incubation with AEF. This 
suggests that the previous exposure to AL amyloid fibrils acts as an AEF to enhance AA 
amyloid formation. In conclusion, AL amyloid fibrils may act as AEF for AA 
amyloidogenesis. 
This could well explain the dual expression of AA and AL amyloidosis in the same patient 














Fig 1. Congo red and haematoxylin staining of cultured monocytes. (a) and (b) Monocytes derived from 
healthy volunteer cultured for 7 days with 150 mg L�1 SAA (a) and AEF (b), showing amyloid (arrows) 
only when cells are simultaneously exposed to AEF. (c) and (d) Monocytes derived from a patient 
suffering from AL amyloidosis incubated only with SAA (c) showing extensive amyloid deposits 
(arrows). No amyloid is seen when cells are cultured in the absence of SAA (d). (e) Detailed image of an 
amyloid deposit from the AL patient showing typical apple-green birefringence under polarized light (f). 
















































































































































































































































































































































































































































































































European Journal of Clinical Investigation (accepted)
Chapter 11
150


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cathepsin D activity protects against development of AA amyloidosis
179
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